First-line erlotinib inferior to chemo in advanced lung cancer
Oncology 26(10): 930-931
2012
ISSN/ISBN: 0890-9091 PMID: 23176004 Document Number: 661061
Document emailed within 1 workday
Related Documents
Imamura, H.; Furukawa, H.; Kishimoto, T.; Miyazaki, Y.; Ohta, K.; Yamamoto, T.; Takemoto, H.; Fukunaga, M.; Ohsato, H.; Tatsuta, M. 2008: A case of advanced gastric cancer treated with chemo-radiotherapy as the fourth-line therapy Gan to Kagaku Ryoho. Cancer and ChemoTherapy 35(12): 2054-2056Senderowicz, A.M.; Johnson, J.R.; Sridhara, R.; Zimmerman, P.; Justice, R.; Pazdur, R. 2007: Erlotinib/gemcitabine for first-line treatment of locally advanced or metastatic adenocarcinoma of the pancreas Oncology 21(14): 1696-1706; Discussion: 1706-1709 1712, 1715
Kodama, I.; Aoyagi, K.; Tanaka, T.; Kumegawa, H.; Ohta, J.; Maruiwa, M.; Kofuji, K.; Takeda, J.; Kakegawa, T. 1993: A case of advanced gastric cancer with liver and lung metastasis effectively treated by combined chemo-immunotherapy of MMC, 5'-DFUR, OK-432 Gan to Kagaku Ryoho. Cancer and ChemoTherapy 20(9): 1237-1240
Nakamura, Y.; Yamamoto, N. 2009: Second-line treatment and targeted therapy of advanced lung cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 36(5): 710-716
Ying Geng, Z.; Chang Jiao, S.; Cui Liu, S.; Li, Y.; Feng Liu, Z.; Qing Zhang, G.; Jie Wang, L.; Qu, F. 2013: Third-line therapy in advanced non-small cell lung cancer Journal of Buon: Official Journal of the Balkan Union of Oncology 18(4): 899-907
Cucević, B.; Samarzija, M.; Baricević, D.; Jakopović, M.; Redzepi, G.; Samija, M. 2005: Gemcitabine in the first and second-line chemotherapy of advanced non-small cell lung cancer Collegium Antropologicum 29(2): 583-588
Thongprasert, S.; Cheewakriangkrai, R.; Napapan, S. 2002: Docetaxel as second-line chemotherapy for advanced non-small cell lung cancer Journal of the Medical Association of Thailand 85(12): 1296-1300
Hashizume, T.; Ogura, T.; Kozawa, S.; Kobayashi, N.; Tagawa, A.; Miyazawa, N.; Watanuki, Y.; Takahashi, H. 2006: Gefitinib as a first-line therapy in patients with advanced non-small cell lung cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 33(4): 467-470
Ryo, H.; Toyama, K.; Isobe, K.; Sugino, K.; Sano, G.; Yamada, H.; Hiroi, M.; Hojyo, T.; Kimura, K. 2003: A phase I study of gemcitabine and irinotecan as second line treatment for advanced non-small cell lung cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 30(2): 237-242
Ciuleanu, T.E.; Curcă, R.; Iancu, D.; Todor, N.; Cebotaru, C.; Radulescu, I.; Banu, E.; Ghilezan, N. 2002: First-line chemotherapy with topotecan and etoposide in advanced small cell lung cancer. a phase Ii study Journal of Buon: Official Journal of the Balkan Union of Oncology 7(1): 43-46
Li, F.; Chen, G.; Jiao, S. 2015: Bevacizumab Combined with Chemotherapy as First-line Therapy for Advanced Non-Small Cell Lung Cancer: A Retrospective Study Hepato-Gastroenterology 62(140): 797-801
Mencoboni, M.; Bergaglio, M.; Serra, M.; Ivaldi, G.P.; Tredici, S.; Racchi, O.; Rebella, L.; Galbusera, V.; Grosso, M.; Faravelli, B. 2007: Maintenance therapy with gefitinib after first-line chemotherapy in patients affected by advanced non-small cell lung cancer Anticancer Research 27(6c): 4425-4429
Morihata, K.; Kimura, M.; Okada, K.; Usami, E.; Nakao, T.; Yoshimura, T.; Hayase, K.; Yasuda, T. 2010: Comparative safety evaluation of first- and second-line therapy with carboplatin + paclitaxel for advanced non-small cell lung cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 37(1): 45-50
Abou-Mourad, Y.; Otrock, Z.K.; Makarem, J.A.; Kattan, J.G.; Farhat, F.S.; Jalloul, R.; Mokaddem, W.T.; Ghosen, M.G.; Taher, A.T.; Chehal, A.A.; Shamseddine, A.I. 2008: Docetaxel and irinotecan as first-line chemotherapy in patients with advanced non-small-cell lung cancer: a pilot study Le Journal Medical Libanais. Lebanese Medical Journal 56(1): 16-21
Shimizu, M.; Miya, T.; Takahashi, A.; Kobayashi, Y.; Kubota, K.; Gemma, A.; Hirose, T. 2017: Nearly Complete Response after Second-Line Therapy with Nab-Paclitaxel Monotherapy in a Patient with Recurrent Advanced Non-Small Cell Lung Cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 44(8): 699-702
Giannakakis, T.; Kakolyris, S.; Theodoropoulos, E.; Kouroussis, C.; Michailakis, E.; Papadouris, S.; Tsitoura, M.; Kalbakis, K.; Souglakos, J.; Agelaki, S.; Vardakis, N.; Georgoulias, V. 2002: A multicenter phase Ii study of docetaxel and carboplatin combination as front-line treatment in advanced non-small cell lung cancer Anticancer Research 22(6b): 3743-3748
Fujiu, K.; Kobayashi, N.; Miyamoto, H.; Suzuki, H. 2012: A case of choroidal metastasis of lung cancer successfully treated with erlotinib Gan to Kagaku Ryoho. Cancer and ChemoTherapy 39(2): 269-271
Khuri, F.R. 2002: Docetaxel for locally advanced or metastatic non-small-cell lung cancer. Current data and future directions as front-line therapy Oncology 16(6 Suppl 6: 53-62
Zhang, J.Q.; Xu, F.; Xu, X.L.; Zhou, H.C. 2017: Erlotinib in the treatment of small cell lung cancer with EGFR mutation: a case report Zhonghua Zhong Liu Za Zhi 39(9): 717-719
Wachters, F.M.; Van Der Graaf, W.T.A.; Groen, H.J.M. 2004: Cardiotoxicity in advanced non-small cell lung cancer patients treated with platinum and non-platinum based combinations as first-line treatment Anticancer Research 24(3b): 2079-2083